Caption Management’s ImmunityBio IBRX Stock Holding History

Caption Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$219K	Sell	25,000 -9,000	-26%	-$68.1K	﹤0.01%	1455
2026 Q1	$261K	Buy	+34,000	New	+$233K	﹤0.01%	1311
2025 Q1	–	Sell	-85,000	Closed	-$218K	–	1758
2024 Q4	$218K	Buy	+85,000	New	+$354K	﹤0.01%	1263
2024 Q2	–	Sell	-266,800	Closed	-$1.43M	–	1316
2024 Q1	$1.43M	Buy	+266,800	New	+$1.21M	0.02%	641
2023 Q2	–	Sell	-60,000	Closed	-$109K	–	1252
2023 Q1	$109K	Buy	+60,000	New	+$187K	﹤0.01%	967

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Caption Management's IBRX Position: Q2 2026 in Review

Caption Management increased its ImmunityBio (IBRX) stake by 970% in Q2 2026, buying an estimated $73.4K and bringing the position to 10,698 shares worth $93.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1526.

Caption Management first reported a position in IBRX in Q1 2024 and has held it in 8 quarters since. The position peaked at $396K in Q1 2024. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Caption Management held 10,698 shares of ImmunityBio worth $93.7K as of Q2 2026.
Caption Management bought 9,698 ImmunityBio shares in Q2 2026, an estimated $73.4K.
ImmunityBio made up ﹤0.01% of Caption Management's portfolio in Q2 2026, its #1526 holding.
Caption Management first reported a position in ImmunityBio in Q1 2024 and has held it in 8 quarters since.
Caption Management's ImmunityBio position peaked at $396K in Q1 2024.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.